Day: April 14, 2023

Perth, April 14, 2023 (GLOBE NEWSWIRE) — QUARTERLY REPORT INVESTOR WEBINAR / CALL Perth, Western Australia/April 14, 2023/ Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its March 2023 Quarterly Results, which are anticipated for release around 8:30am AEST on Wednesday April 19, 2023. CALL DETAILSAustralia: Wednesday April 19, 2023 Perth – 7:00am Sydney/Melbourne – 9:00am Canada: Tuesday April 18, 2023 Vancouver – 4:00pm Toronto – 7:00pm UK: Wednesday April 19, 2023 London – 12:00amRegister for the investor webinar at the link below: https://us02web.zoom.us/webinar/register/WN_jWTIfxKxSQCJ-OAvinLQIw After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one of the following...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved.  No other deficiencies in the application were noted by the FDA.  Alvotech provided the FDA comprehensive responses to the inspection observations on April 3, 2023, and is awaiting communication from the agency assessing those...

REYKJAVIK, Iceland, April 14, 2023 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved. No other deficiencies in the application were noted by the FDA. Alvotech provided the FDA comprehensive responses to the inspection observations on April 3, 2023, and...

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES TORONTO, April 13, 2023 (GLOBE NEWSWIRE) — MacDonald Mines Exploration Ltd. (the “Company”) (TSX-V: BMK) has agreed to settle outstanding amounts owing to a departed executed through the issuance of Class A common shares of the Company (the “Common Shares”) in accordance with applicable shares-for-debt policies of the TSX Venture Exchange (the “TSXV”). The Company and the former executive have entered into a debt settlement agreement which provided that the aggregate amount of the debt owed to such executive is $12,500 and will be settled by the issuance of 178,572 Common Shares at a deemed price of $0.07 per Common Share (the “Shares for Debt Transaction”). The issuance of the Common Shares is subject to the receipt of all applicable regulatory approvals,...